Search the Newsreel

Galectin Therapeutics Inc (GALT) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Galectin Therapeutics Inc (GALT), detailing its support, resistance levels, and various technical indicators. It presents a summary of buy, sell, and neutral signals from indicators like MACD, RSI, and moving averages, concluding with a neutral overall signal …

Alector (ALEC) Expected to Post Quarterly Earnings on Thursday

Alector (ALEC) is scheduled to release its Q2 2026 earnings before market open on Thursday, August 6th, with analysts forecasting a loss of $0.24 per share and revenue of $1.43 million. This follows a Q1 report where the company beat EPS estimates but significantly …

Galectin Therapeutics Inc. Revenue Breakdown – NASDAQ:GALT

This page provides financial overview information for Galectin Therapeutics Inc. (NASDAQ: GALT). It details access to financial statements, statistics, dividends, earnings, and segment performance. The page is part of TradingView, which offers various market analysis tools and data.

ALEC|Alector Inc|Price:1.640|Chg%:+0.120

Alector Inc (ALEC) has received an overall TradingKey Stock Score of 5.79/10, indicating stable fundamentals and significant growth potential, although its valuation is considered fairly valued. Institutional ownership is very high, and analysts have recently rated the stock as "Hold" with a target price …

Alector Inc (ALEC) Valuation: PE, PB & Fair Value Analysis

This article analyzes the valuation of Alector Inc (ALEC), noting its current valuation score of 6.90 within the Biotechnology & Medical Research industry. It highlights the company's current P/E ratio of -1.28 and mentions that relevant data for P/B, P/S, and P/CF ratios have …

Galectin Therapeutics Inc (GALT) Financial Health: Profitability & Balance Sheet Analysis

This article provides a brief overview of Galectin Therapeutics Inc (GALT)'s financial health, focusing on profitability and balance sheet analysis. It presents current stock price, market capitalization, and a prompt for more detailed financial and analysis information. The content also notes the absence of …

Galectin Therapeutics Inc (GALT) Cash Flow

This article provides a detailed cash flow statement for Galectin Therapeutics Inc (GALT), categorizing quarterly financial data into operating, investing, and financing cash flows from FY2012Q1 to FY2026Q1. It includes a market overview with current stock price, market cap, and P/E, alongside FAQs explaining …

Alector Inc (ALEC) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Alector Inc (ALEC), listing major shareholders and their proportional holdings, as well as the types of shareholders. It also provides a historical overview of institutional shareholding, including the number of institutions, shares held, and changes over recent …

Alector Inc (ALEC) Cash Flow Statement

This article provides Alector Inc's (ALEC) cash flow statements, including quarterly and annual data for operating, investing, and financing activities. It also defines these cash flow types and free cash flow, explaining their importance for evaluating a company's financial health, with specific figures for …

Alector Inc (ALEC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey provides a revenue breakdown for Alector Inc (ALEC), noting that relevant data regarding business segments, regional revenue, and profit contribution has not yet been disclosed by the company. It briefly presents the stock’s current trading information, including its market cap …

ALEC|Alector Inc|Price:1.520|Chg%:+0.040

Alector Inc. (ALEC) is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company's pipeline includes latozinemab and AL101/GSK4527226, targeting progranulin levels, and several preclinical candidates utilizing its ABC blood-brain barrier platform. ALEC's stock information, executive team, and institutional ownership details …

TradingKey

This article provides a detailed balance sheet analysis for Galectin Therapeutics Inc (GALT), displaying quarterly and annual data for various assets, liabilities, and shareholder equity components. It highlights key financial figures such as total assets, current assets, non-current assets, total liabilities, and total shareholders' …

GALT|Galectin Therapeutics Inc|Price:3.390|Chg%:-0.080

This article from TradingKey provides an overview and analysis of Galectin Therapeutics Inc (GALT). It details the methodology behind TradingKey's comprehensive Stock Score, which assesses companies based on 34 indicators across six dimensions, including financial health, earnings forecasts, and institutional confidence. However, it notes …

Spruce Street Capital LP Buys 983,082 Shares of Alector, Inc. $ALEC

Spruce Street Capital LP significantly increased its stake in Alector, Inc. (NASDAQ:ALEC) by 87.9% in the first quarter, purchasing an additional 983,082 shares to bring its total holding to over 2.1 million shares, representing about 1.89% of the company. Alector's stock recently traded down …

GALT stock reacts to Galectin Therapeutics Q1 2026 cash position and R&D progress

Galectin Therapeutics Inc. (GALT) reported its Q1 2026 financials, showing a cash position of $25.4 million, down from $32.7 million in Q4 2025 due to increased research and development (R&D) spending. The company's net loss widened to $8.1 million as R&D expenses rose by …

Galectin Therapeutics (NASDAQ:GALT) Stock Passes Above 200-Day Moving Average - Here's Why

Alector, Inc. (NASDAQ:ALEC) Receives Average Recommendation of "Hold" from Analysts

Alector, Inc. (NASDAQ:ALEC) has an average analyst rating of "Hold" based on eight analysts, with a target price of $3.63. Recent insider selling by the CFO and CEO totaled 115,760 shares, and the stock is trading near its 52-week low. Despite reporting a smaller-than-expected …

GALT stock gains support as Galectin Therapeutics keeps cash focus

Galectin Therapeutics (GALT) is being evaluated based on its cash reserves, R&D expenses, and clinical trial progress for its lead program, belapectin, rather than revenue. The company reported $21.5 million in cash and cash equivalents and $5.9 million in R&D expenses for Q1 2026, …

Form 4 Galectin Therapeutics Inc For: 16 July By Investing.com

This article reports on the Form 4 filing for Galectin Therapeutics Inc., which was published on July 16, 2026. Form 4s disclose changes in beneficial ownership of securities by company insiders. The article uses a standard format provided by Investing.com for regulatory filings but …

Galectin Therapeutics CMO Jamil Khurram sells $83,284 in stock

Jamil Khurram, Chief Medical Officer of Galectin Therapeutics Inc., sold 16,250 shares of common stock for $83,284 on July 14, 2026, under a Rule 10b5-1 trading plan. This sale occurred after he exercised stock options for the same number of shares at a lower …

Galectin Therapeutics (GALT) CMO sells 16,250 shares under 10b5-1 plan

Galectin Therapeutics Chief Medical Officer Jamil Khurram exercised stock options to acquire 16,250 common shares at $3.04 each and subsequently sold all 16,250 shares at a weighted average price of $5.1252 on July 14, 2026. This transaction was conducted under a Rule 10b5-1 trading …

GALT Forecast — Price Target — Prediction for 2027

Galectin Therapeutics (GALT) Announces FDA Agreement for Phase 3 Program

Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension

GALT Q1 2026 Earnings: Clinical-Stage Biotech Reports Wider-Than-Expected Loss as Stock Edges Higher - Net Profit Margin

Galectin Therapeutics (GALT) Slips 1.87% as Shares Consolidate Near Key Support - Revenue Growth Stocks

Galectin Therapeutics Q1 2026 Earnings: EPS Misses Estimates, Stock Rallies on Operational Progress - Cost Structure Review

Galectin Therapeutics (GALT) Earnings Date and Reports 2026 $GALT

Galectin Therapeutics (GALT) Upgraded to Buy: What Does It Mean for the Stock?

Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update

Galectin Therapeutics (GALT) Stock Price, News & Analysis

Galectin Therapeutics (GALT)

Galectin Therapeutics (GALT) Stock Price, News & Analysis $GALT